End-stage Renal Disease, Hypertension
Conditions
Brief summary
Sympathetic activation is a hallmark of end-stage renal disease and adversely affects cardiovascular prognosis. Hypertension is present in the vast majority of these patients and plays a key role in the progressive deterioration of renal function and in the exceedingly high rate of cardiovascular events. Selective catheter-based renal denervation has been shown to be safe and effective in attaining improved and sustained blood pressure control in patients with resistant hypertension and normal renal function. The investigators hypothesize that catheter-based renal denervation is a safe and effective intervention to achieve sustained reduction in sympathetic nerve activity, BP and target organ damage in hypertensive End-Stage Renal Disease (ESRD) patients, which will result in improved cardiovascular outcomes.
Interventions
PROCEDURERenal Denervation
Renal Denervation
Sponsors
Baker Heart and Diabetes Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* end stage renal disease * hypertension (BP≥140/90mmHg)
Exclusion criteria
* Individual has renal artery anatomy that is ineligible for treatment as assessed by the interventionalist. * Individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood Pressure change | 6 months | Difference in the reduction of systolic office blood pressure between the renal denervation and control group at 6 months after the procedure |
Countries
Australia
Outcome results
None listed